Highest-materiality recent filing
Indaptus discontinues Decoy20 enrollment, no active clinical programs; Q2 net loss $1.8M
Q2 2026 net loss $1.8M vs $5.2M in Q2 2025; six-month loss $4.3M vs $9.8M; EPS loss $0.02 vs $9.09.
Indaptus Therapeutics Q1 2026 net loss $2.5M; cash burn concerns with only $1.5M left
Q1 2026 net loss narrowed to $2.5M vs $4.5M YoY; loss per share $0.23 (post reverse split).
Indaptus Therapeutics appoints Yu Ding as CFO, Qinglai Lu to board; CFO Nir Sassi resigns
Nir Sassi resigned as CFO effective April 1, 2026; resignation not due to disagreement.
Indaptus Therapeutics change of control: David Lazar sells $11.2M stake; new CEO Junyi Dai appointed
David Lazar sold 700K Series AAA and 196.8K Series AA Preferred shares to five purchasers for $11.2M.
Indaptus stockholders approve proposals enabling David Lazar to obtain 96.4% control; board changes
Lazar purchased $6.0M of preferred stock; upon conversion, 111M common shares issuable, representing ~96.4% of fully diluted outstanding.
Indaptus cuts co-CEO and CSO salaries to $60K/year; director rescinds resignation
Co-CEO Jeffrey A. Meckler and CSO Michael J. Newman salaries reduced to $60,000 per annum effective Jan 15, 2026.
Three Indaptus Therapeutics directors resign pending stockholder vote on Lazar nominees
Directors Michael Newman, Mark Gilbert, Anthony Maddaluna resigned effective upon approval of David Lazar's nominees at next stockholder meeting.
Indaptus raises $6M via convertible preferred; Lazar appointed Chairman and Co-CEO
David Lazar invests $6M for 300K Series AA and 700K Series AAA shares convertible into 111M common shares after stockholder approval.
Q3 2025 loss per share $2.98 vs $9.04 YoY; cash $5.8M at Sept 30, expected to fund into Q1 2026.
Indaptus reports partial response in Decoy20 monotherapy; raises $5.7M
Decoy20 monotherapy induced partial response (liver metastases reduction) in one urothelial cancer patient; later disease progression.
Indaptus reports Q2 net loss $9.09/sh; first patient dosed in Decoy20 combo trial with tislelizumab
Q2 2025 R&D expenses $2.2M (up $0.5M YoY); G&A $2.3M (down $0.1M YoY); net loss per share $9.09 vs. $13.16.
Raised gross proceeds of approximately $5.7 million in private placement of convertible notes and warrants, closed June 12 and June 30, 2025.
Indaptus raises additional $3.4M via convertible notes and warrants, total $5.7M
Second closing of private placement adds $3.4M in convertible notes; aggregate gross proceeds now $5.7M.
Indaptus Therapeutics implements 1-for-28 reverse stock split effective June 26, 2025
Reverse stock split at ratio of 1-for-28 effective after market close on June 26, 2025.
Indaptus raises $2.3M via convertible notes and warrants; up to $5M total
$2.3M aggregate principal of 6% convertible promissory notes; mature July 28, 2026.
Cash and equivalents $3.9M at March 31, 2025, down from $5.8M at Dec 31, 2024; Company needs additional capital beyond Q2 2025.
Indaptus reports Q4 loss per share $1.61; cash $5.8M; Decoy20 trial enrolls >20 patients
Cash and equivalents $5.8M as of Dec 31, 2024; Jan 2025 private placement raised net $2.0M.
Indaptus enters $20M standby equity line with Yorkville; issues 305,960 commitment shares
Up to $20M equity purchase agreement with YA II PN (Yorkville) over 36 months.
Indaptus receives Nasdaq deficiency notice for bid price below $1.00; 180-day cure period
Received Nasdaq notice on Jan 31, 2025 for non-compliance with minimum bid price of $1.00 per share.
Indaptus raises $2.25M in private placement of stock and warrants at $1.065/unit
Gross proceeds of $2.25M from sale of 2,109,383 shares and warrants to purchase 2,109,383 shares (combined price $1.065/unit).
Indaptus Therapeutics prices $2.135M offering of stock and warrants at $1.175/unit
Sold 1,817,017 shares of common stock and warrants to buy 1,817,017 shares at $1.175 per unit.
Indaptus Q3 2024: EPS -$0.32, cash $7.4M; Decoy20 Phase 1 expands with BeiGene deal
Q3 2024 net loss $0.32 per share (vs $0.47 loss in Q3 2023); nine-month loss $1.23 per share (vs $1.36 loss).
Indaptus advances Decoy20 Phase I trial; first patient dosed in multi-dose portion
Safety Review Committee reviewed initial Decoy20 clinical data; data to be presented at ASCO 2024.
Indaptus Therapeutics reports Q1 2024 results; R&D expense down 15% YoY
R&D expenses $1.6M, down $0.3M or 15% vs Q1 2023; G&A expenses $2.4M, down 9%.
Indaptus reports FY2023 loss of $1.83/sh; cash $13.4M; Phase 1 Decoy20 advancing
FY2023 net loss per share $1.83 vs $1.73 in FY2022; cash at Dec 31, 2023 was $13.4M (down from $26.4M).
Indaptus reports positive Phase 1 results for Decoy20; moves to multi-dose trial
Second cohort of Phase 1 INDP-D101 trial showed broad immune response consistent with first cohort.
Indaptus presents Phase 1 Decoy20 interim data: stable disease in all 4 patients
All four patients in first cohort showed stable disease at 4 weeks; three had progressive disease at baseline.
Indaptus Q3 2023 net loss $0.47/share; cash $16M into Q2 2024; Decoy20 all 4 patients stable disease
Cash and equivalents $16.0M as of Sep 30, 2023, down from $26.4M at Dec 31, 2022; runway into Q2 2024.
Indaptus completes first Decoy20 cohort; starts second cohort
Three patients completed 28-day safety review; one grade 3 bradycardia (reversible) and two grade 3 AST increases resolved.
Indaptus Therapeutics Q1 2023 net loss $0.51/sh; cash $21.7M, runway into Q2 2024
R&D expenses $1.9M (+$0.6M YoY); G&A $2.6M (+$0.5M YoY); net loss per share $0.51 vs $0.41.
Indaptus Therapeutics Q4/FY2022: Loss per share $1.73, cash $26.4M; Phase 1 Decoy20 trial underway
R&D expense $1.9M in Q4 (up 90% YoY); FY R&D $6.3M (up 150% YoY).
Effective as of June 5, 2026, Mr. David E. Lazar and Mr. Avraham Ben-Tzvi resigned from all directorship positions, including from all committees served, on the Board of Directors (the “ Board ”) of Indaptus Therapeutics, Inc. (the “ Company ”).
Effective as of June 1, 2026, Mr. Walt A. Linscott, Esq. resigned as the Chief Operating Officer of the Company, and, pursuant to a consulting agreement with the Company dated June 1, 2026, will serve as a consultant for the Company.
Effective as of June 5, 2026, Mr. David E. Lazar and Mr. Avraham Ben-Tzvi resigned from all directorship positions, including from all committees served, on the Board of Directors (the “ Board ”) of Indaptus Therapeutics, Inc. (the “ Company ”).
On March 22, 2023, the Board appointed Walt A. Linscott, the Company's Chief Business Officer, as the Company's Chief Operating Officer, effective immediately.
On February 13, 2023 (the “Effective Date”), the Board of Directors (the “Board”) of Indaptus Therapeutics, Inc. (the “Company”) increased its size to provide for a total of nine directors authorized to serve on the Board and appointed Robert Martell, M.D., Ph.D. as a Class I director of the Company.
On February 1, 2022, Intec Pharma Ltd. (“Intec”), a wholly owned subsidiary of Indaptus Therapeutics, Inc. (the “Company”) entered into an employment agreement (the “Employment Agreement”) with Nir Sassi, the Company’s Chief Financial Officer.
On November 29, 2021, Mr. Hoonmo Lee tendered his resignation from the Board of Directors (the “Board”) of Indaptus Therapeutics, Inc. (the “Company”), and from all committees of the Board.
On the same day, the Board elected Mark J. Gilbert, M.D. as a member of the Board, effective immediately.
each of Michael Newman, Ph.D., Hoonmo Lee and Brian O’Callaghan were appointed as directors of the Company.
Michael Newman, Ph.D. was appointed as Chief Scientific Officer.
each of Michael Newman, Ph.D., Hoonmo Lee and Brian O’Callaghan were appointed as directors of the Company.
each of Michael Newman, Ph.D., Hoonmo Lee and Brian O’Callaghan were appointed as directors of the Company.
Max materiality 1.00 · Median 0.60 · Most common event other_material